These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18497518)

  • 1. Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.
    Hofheinz RD; Beyer U; Al-Batran SE; Hartmann JT
    Onkologie; 2008 May; 31(5):271-81. PubMed ID: 18497518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Practical impact of pharmacologic and clinical data on early post-operative instillation of mitomycin C].
    Bonnal JL
    Prog Urol; 2002 Feb; 12(1):118-23. PubMed ID: 11980004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent clinical trials summary.
    Nathanson DR; Thomas CR; Bleday R
    Surg Oncol Clin N Am; 2004 Apr; 13(2):389-94. PubMed ID: 15137964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of controlled-release preparation of mitomycin C in the treatment of inoperable cancer patients].
    Hanyu F; Nakamura M; Takasaki T; Kasai Y; Sato T; Sato H; Sakurai Y; Yamada A; Okawa T; Sakabe T
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3087-93. PubMed ID: 2461168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma].
    Qu QL; Zhang YG; Yang LZ; Sun L
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):257-60. PubMed ID: 16875622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin C: a clinical update.
    Bradner WT
    Cancer Treat Rev; 2001 Feb; 27(1):35-50. PubMed ID: 11237776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor.
    Xi-Xiao Y; Jan-Hai C; Shi-Ting L; Dan G; Xv-Xin Z
    Regul Toxicol Pharmacol; 2006 Dec; 46(3):211-7. PubMed ID: 17010489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Update on the treatment of common gastrointestinal malignancies].
    Wolf I; Catane R; Symon Z; Papa MZ; Fider HH
    Harefuah; 2005 Jan; 144(1):39-44, 70. PubMed ID: 15719821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
    Ather MH; Aziz S; Sulaiman MN
    J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitomycin C in patients with gynecological malignancies.
    Kahmann L; Beyer U; Mehlhorn G; Thiel FC; Strnad V; Fasching PA; Lux MP
    Onkologie; 2010; 33(10):547-57. PubMed ID: 20926904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
    Stoehr B; Mueller T; Granig T; Zangerl F; Steiner H
    BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers.
    Averbach AM; Stuart OA; Sugarbaker TA; Stephens AD; Fernandez-Trigo V; Shamsa F; Sugarbaker PH
    Ann Surg Oncol; 1995 Jul; 2(4):325-31. PubMed ID: 7552622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nine-year follow-up of trabeculectomy with or without low-dosage mitomycin-c in primary open-angle glaucoma.
    Reibaldi A; Uva MG; Longo A
    Br J Ophthalmol; 2008 Dec; 92(12):1666-70. PubMed ID: 18782799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
    Dalbagni G
    Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.
    Bilensoy E; Sarisozen C; Esendağli G; Doğan AL; Aktaş Y; Sen M; Mungan NA
    Int J Pharm; 2009 Apr; 371(1-2):170-6. PubMed ID: 19135514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mitomycin C: current status of knowledge and use in laryngeal tumors].
    Giorgi G; Bertelli E; Salvini M; Aragona P
    Arch Sci Med (Torino); 1983; 140(1):45-50. PubMed ID: 6409052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gastrointestinal oncology - therapy update 2008 / 2009].
    Ebert MP; Auernhammer C; Caca K; Eckel F; Fischbach W; Geissler M; Göke B; Greten T; Kubicka S; Lutz MP; Möhler M; Opitz O; Pavel M; Porschen R; Reinacher-Schick A; Schmiegel W; Seufferlein T; Wiedenmann B; Schmid RM
    Z Gastroenterol; 2009 Mar; 47(3):296-306. PubMed ID: 19267319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
    Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
    Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
    Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.